Navigation Links
New Venture Funding for Alzheimer's Disease Drug Developer
Date:1/12/2009

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder. The company has raised $7.4 million to date in equity funding.

Venture Investors (VI - Madison, Wis.) led this latest round of financing. The State of Wisconsin Investment Board and Wisconsin Investment Partners, both of Madison, Wis., and Rocket Venture Fund (Toledo. Ohio), all existing shareholders, also participated in the latest funding. Mithridion plans to hold a final closing with respect to this financing on or before March 31, 2009.

John Neis, Managing Director of VI, will join Mithridion's board of directors.

"This new funding will enable Mithridion not only to advance MCD-386 in Phase I trial, but will also support the development of exciting drug leads for AD and schizophrenia in our preclinical pipeline," said Trevor M. Twose, Ph.D., the company's Chief Executive. "We greatly appreciate the continued support of our shareholders," he added.

Five million Americans suffer from Alzheimer's disease today, and the number will grow as baby-boomers age. The market for Alzheimer's disease drugs exceeds $4 billion, but is currently underserved, and may grow to greater than $10 billion with the development of drugs that are more effective.

MCD-386 is highly selective for the M1-type muscarinic receptor. In preclinical laboratory tests, MCD-386 appears to replace deficient brain acetylcholine activity, similar to that caused by AD. This drug is intended to improve memory and cognition
'/>"/>

SOURCE Mithridion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
2. NTU and Insightra Medical Inc. release their first joint venture medical device
3. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
4. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
5. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
6. Venture Health Group Selects Planet DDS Web-based Practice Management Software
7. HLM Venture Partners Leads Series B Financing of CaseNET, Inc.
8. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
9. MM2 Group Establishes New Venture for Sofgel Manufacture in China
10. Radius Ventures Announces Promotion of Dr. David Stoffel to Partner
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Greatist ... newsletter and website that helps active people find the most fun activities to do ... lifestyle coverage for millennials. It also increases Greatist’s opportunity for events, e-commerce, and brand ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of advanced delivery technologies and development solutions for drugs, biologics and consumer ... with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Healthpointe is proud to ... Alupay, an anesthesiologist and pain management specialist, will be evaluating and treating patients with ... conditions. , After receiving his Bachelor of Science in Biology from the University of ...
(Date:7/7/2015)... ... July 07, 2015 , ... Georgia Partnership for ... communities throughout Georgia, announces the launch of the first ambulance telemedicine program in ... County, GA. The new program will not only provide more immediate patient care, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Bayco’s Nightstick® ... the introduction of the Nightstick XPP-5422GM , the world’s first Intrinsically Safe ... its base and one on its clip. The new Nightstick XPP-5422GM is now ...
Breaking Medicine News(10 mins):Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3
... Dermatologists say that paying extra for expensive vitamins in skin ... will get you little more than an empty wallet.//,Antioxidants are ... in the body and the skin.Free radicals are a result ... by exposure to various environmental factors such as smoking or ...
... are often concerned that toxins within the environment ... by these couples to their health care providers ... regarding the reproductive impact of potential environmental toxins ... ,Heavy metals such as lead and mercury, ...
... when someone who talks about suicide will actually go ... depressed patients need protection.Now American scientists believe that// they ... test that checks glands controlling the stress hormone cortisol. ... the mental turmoil that leads people to take the ...
... cells in the lens of the eye become cloudy. It ... states that eating a diet rich in Vitamin C could ... Nutrition looked at nearly 400 people aged between 53 and ... supplements they were taking. Overall, 35% had "cortical opacities", a ...
... a more effective vaccine for anthrax and they claim that ... which is presently available.It has been developed by a team, ... by Dr Rakesh Bhatnagar. ,It is made up of ... the toxin that does the damage to humans infected with ...
... a decreased white blood cell function can lead to ... at six weeks of age the// genetically engineered mice ... the normal mice had no bone loss. The ... is an indication of periodontitis. ,The scientists also ...
Cached Medicine News:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: